Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 1 |
| Operating profit | $m | -8 | -9 | ||||||
| Net profit | $m | -3 | -4 | -6 | -4 | -8 | -7 | -8 | - |
| EPS reported | $ | -11.73 | -6.05 | ||||||
| Operating cashflow per share | $ | -10.22 | -3.31 | ||||||
| Capex per share | $ | 0.33 | 0.07 | ||||||
| FCF per share | $ | -10.54 | -3.37 | ||||||
| Free cash flow | $m | -7 | -9 | ||||||
| Net debt | $m | -3 | -1 | ||||||
| Book value equity | $m | 3 | 3 | ||||||
| Book value per share | $ | 5.17 | 0.99 | ||||||
| Number of shares | m | 0.67 | 2.65 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.39 | 1.87 | ||||||
| P/S LTM | x | 1.35 | 4.40 | ||||||
| P/FCF LTM | x | -0.19 | -0.55 | ||||||
| EV/EBITDA LTM | x | -0.00 | -0.50 | ||||||
| EV/Sales LTM | x | 0.00 | 3.62 | ||||||
| Earnings Yield LTM | % | -541.58% | -219.93% | ||||||
| FCF Yield | % | -519.44% | -183.08% | ||||||
| Quality | |||||||||
| ROE | % | -212.76% | -211.59% | ||||||
| ROIC | % | -219.65% | -321.21% | ||||||
| Operating margin | % | -771.64% | -774.90% | ||||||
| Gross margin | % | 22.26% | 19.42% | ||||||
| FCF/Sales | % | -702.87% | -805.62% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +65.49% | +68.02% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -46.26 | -59.20 | ||||||
| Net Debt/EBITDA | x | 0.19 | 0.11 | ||||||
| EBIT/Net interest | x | -994.05 | -1,134.85 | ||||||
| Net debt/market cap | % | -190.96% | -17.83% | ||||||
| Net debt/Equity | x | -0.75 | -0.33 | ||||||
| Gross debt/equity | x | 0.04 | 0.06 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
60 Degrees Pharmaceuticals, Inc. (SXTP)
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free